Live news related to ARGENX SE stock (NL0010832176): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
Belgian biotech company Argenx announced on Wednesday its participation in two major investor conferences in the United States in June. Members of its…
Argenx announced on Friday that the U.S. FDA has approved an expanded indication for Vyvgart and Vyvgart Hytrulo, making them the first and only appro…
Argenx released its Q1 2026 results on Thursday, showing a net profit of $366 million, up from $169 million a year earlier, a 116% increase. Basic ear…
Argenx has announced the appointment of Karen Massey as CEO by the board of directors, following shareholder approval of her addition to the board.
The biopharmaceutical group argenx announces the presentation of new clinical data for VYVGART and its drug candidates at the annual American Academy …
Argenx announces its annual general meeting on May 6, 2026, in the Netherlands. The meeting will include the review of the 2025 financial statements a…
Argenx announces through a press release that it will present new clinical data at the American Academy of Neurology (AAN) annual conference in April …
Argenx laboratory revealed on Thursday the positive results of its phase 3 ADAPT OCULUS clinical trial evaluating Vyvgart in the treatment of ocular m…
Argenx announces the participation of its Chief Operating Officer in a presentation at the 46th annual TD Cowen Health Conference. The event will take…
Goldman Sachs ajuste son objectif de cours sur argenX SE ce vendredi 13 février 2026.
